13. **Kunishio K**, Nagao S. Prognostic implication of p27 expression in primary central nervous system lymphoma. *Brain Tumor Pathol* 2006;**23**:77–81.
14. **Wolowiec D**, Wojtowicz M, Ciszak L, *et al*. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. *Eur J Haematol* 2009;**82**:260–6.
15. **Bales ES**, Dietrich C, Bandyopadhyay D, *et al*. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. *J Invest Dermatol* 1999;**113**:1039–46.
16. **Nakatsuka S**, Liu A, Yao M, *et al*. Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. *Int J Oncol* 2003;**22**:561–8.
17. **Chang BL**, Zheng SL, Isaacs SD, *et al*. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. *Cancer Res* 2004;**64**:1997–9.
18. **Pellegata NS**, Quintanilla-Martinez L, Siggelkow H, *et al*. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. *Proc Natl Acad Sci U S A* 2006;**103**:15558–63.
19. **St Croix B**, Florenes VA, Rak JW, *et al*. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. *Nat Med* 1996;**2**:1204–10.
20. **Sanchez-Beato M**, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. *Blood* 2003;**101**:1220–35.
21. **Rassidakis GZ**, Feretzaki M, Atwell C, *et al*. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. *Blood* 2005;**105**:827–9.
22. **Bai M**, Tsanou E, Skyras A, *et al*. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas. *Anticancer Res* 2007;**27**:2345–52.
23. **Barnouin K**, Fredersdorf S, Eddaoudi A, *et al*. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. *Oncogene* 1999;**18**:6388–97.
24. **Erlanson M**, Portin C, Linderholm B, *et al*. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. *Blood* 1998;**92**:770–7.
25. **Cheng N**, van de Wetering CI, Knudson CM. p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma. *PLoS One* 2008;**3**:e1911.
26. **Uner AH**, Saglam A, Han U, *et al*. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. *Leuk Lymphoma* 2005;**46**:1463–70.
27. **Schondorf T**, Eisele L, Gohring UJ, *et al*. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. *Tumour Biol* 2004;**25**:306–12.
28. **Kibel AS**, Suarez BK, Belani J, *et al*. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. *Cancer Res* 2003;**63**:2033–6.
29. **Cave H**, Martin E, Devaux I, *et al*. Identification of a polymorphism in the coding region of the p27Kip1 gene. *Ann Genet* 1995;**38**:108.
30. **Hartmann S**, Gesk S, Scholtysik R, *et al*. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. *Br J Haematol* 2010;**148**:402–12.
31. **Nakayama K**, Ishida N, Shirane M, *et al*. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. *Cell* 1996;**85**:707–20.
32. **Kiyokawa H**, Kineman RD, Manova-Todorova KO, *et al*. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). *Cell* 1996;**85**:721–32.
33. **Gazzola A**, Bertuzzi C, Agostinelli C, *et al*. Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. *Haematologica* 2009;**94**:1036–7.

Correction

Orsolya D, Ungvári A, Kardos S, *et al*. Genotypic and phenotypic characterisation of invasive *Streptococcus pneumoniae* isolates from Hungary, and coverage of the conjugate vaccines. *J Clin Pathol* 2010;**63**:1116–20. Table 1 in this article should read as below:

Table 1 Antibiotic susceptibility of the 144 pneumococcal isolates

Antibiotic	MIC (mg/l)			% R	% I	% S
	MIC ₅₀	MIC ₉₀	Range			
Penicillin	0.03	1	0.004–4	1.4	37.6	61.0
Cefotaxime	0.016	0.5	0.004–2	0	6.3	93.7
Imipenem	0.016	0.25	0.004–2	0	0	100
Erythromycin	0.19	512	0.6–>512	38.5	2.1	59.4
Clindamycin	0.25	256	0.03–>512	31.8	0	68.2
Telithromycin	0.015	0.06	0.004–0.5	0	0	100
Levofloxacin	0.75	1	0.38–8	1.4	0	98.6
Moxifloxacin	0.25	0.5	0.03–1	3.5	0	96.5
Vancomycin	0.5	1	0.125–1	0	0	100

J Clin Pathol 2011;**64**:87. doi:10.1136/jcp.2010.079780corr1